Skip Navigation Links
   
Skip Navigation Links
   

Lung Cancer - Adjuvant


ALCHEMIST SCREENING STUDY:  Genetic Testing in Screening Patients With Stage IB-IIIA Non-Squamous Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery   A151216 (NCT02194738)   (MBMC Contact: Missy Kuhn 314-996-5868    

-  ALCHEMIST Treatment Study:  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (Erlotinib/Placebo Provided)  (Must have Consented to ALCHEMIST A151216 Trial)  A081105 (NCT02193282)  (MBMC Contact: Missy Kuhn 314-996-5868  

-  ALCHEMIST Treatment Study:  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations  (Crizotinib/Placebo Provided)      (Must have Consented to ALCHEMIST A151216 Trial)  ECOG E4512 (NCT02201992)   (MBMC Contact: Missy Kuhn 314-996-5868  

-  ALCHEMIST Treatment Study:  Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers  EA5142 (NCT02595944)   (MBMC Contact:  Missy Kuhn 314-996-5868)

 

Melanoma Trials in St. Louis, MO
 
 

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy